In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Enzalutamide With or Without Abiraterone Acetate and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIIBiomarker/Laboratory analysis, TreatmentActive18 and overNCI, OtherA031201
U10CA031946, NCI-2013-01737, NCT01949337

Trial Description

Summary

This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone acetate, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.

Further Study Information

Patients are randomized to one of two treatment groups: enzalutamide or enzalutamide, abiraterone and prednisone. Treatment will continue until disease progression or unacceptable toxicity. Patients are followed for clinical outcomes for a maximum of 5 years post study treatment. The primary and secondary objectives are described below.

1. Primary Objective:

To compare the overall survival of patients with progressive metastatic castration-resistant prostate cancer (CRPC) treated with either enzalutamide only or enzalutamide with abiraterone (abiraterone acetate) and prednisone

2. Secondary Objectives:

  • To assess the grade 3 or higher toxicity profile and compare safety by treatment arm.
  • To assess and compare post-treatment prostate-specific antigen (PSA) declines by treatment arm.
  • To compare radiographic progression free survival defined by Prostate Cancer Working Group 2 (PCWG2), and objective response rate, by treatment arm.
  • To test for radiographic progression free survival (rPFS) treatment interaction in predicting overall survival.
  • To assess pre- and post-treatment measures of tumor burden and bone activity using sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (CT) and technetium (Tc) methylene diphosphonate (MDP) bone scintigraphy and correlate these measures with overall survival.
  • To develop and validate prognostic and predictive models of overall survival that include baseline clinical and molecular markers.

Eligibility Criteria

Eligibility Criteria:

1. Documentation of Disease - Progressive castration-resistant metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features

2. Patients must have measurable or non-measurable disease:

1. Measurable Disease - For visceral or extra nodal lesions to be considered measurable, they must be ≥ 10 mm in one dimension, using spiral CT. For lymph nodes to be considered measurable (ie, target or evaluable lesions), they must be ≥ 20 mm in at least one dimension, using spiral CT.

2. Non-Measurable Disease - All other lesions, including small lesions (longest diameter < 20 mm with conventional techniques or < 10 mm with spiral CT scan) and truly non-measurable lesions. Lesions that are considered non-measurable include bone lesions (only).

3. Progressive Disease - Patients must have progressive disease at study entry defined as one or more of the following three criteria that occurred while the patient was on androgen deprivation therapy. For patients enrolling on the basis of soft tissue or bone progression, the baseline scan must show progression relative to a comparison scan. If the comparison scan is not available, the baseline scan report must reference the previous scan to document progression.

1. PSA progression defined by a minimum of two rising PSA levels with an interval of ≥ 1 week between each determination. Patients who received an anti-androgen must have progression documented by a minimum of two rising PSA levels with an interval of ≥ 1 week between each determination such that at least the second of these rises is ≥ 4 weeks since last flutamide or ≥ 6 weeks since last bicalutamide or nilutamide. The PSA value at the screening should be ≥ 2 µg/L (2 ng/mL)

2. Soft tissue disease progression defined by the protocol

3. Bone disease progression defined by the Prostate Cancer Working Group 2 (PCWG2) with two or more new lesions on bone scan

4. Prior Treatment

1. No treatment with prior taxane-based chemotherapy for metastatic disease

  • Patients who received prior taxane-based chemotherapy as neoadjuvant or adjuvant therapy for local disease, or who received taxane-based therapy in the PSA clinical (non-metastatic) state is allowable provided that the total duration of exposure was six cycles or less and chemotherapy was completed more than 6 months prior to registration
  • Taxane-based chemotherapy that was aborted due to allergic reactions or intolerance to chemotherapy and therefore received one cycle of prior therapy is allowable

2. No prior enzalutamide, abiraterone or other novel antiandrogen or androgen synthesis inhibitor

3. No treatment with any of the following for prostate cancer within 4 weeks prior to enrollment:

  • Hormonal therapy (e.g., androgen receptor [AR] antagonists, 5 alpha reductase inhibitors, estrogens) Note: Treatment with bicalutamide and nilutamide within 6 weeks prior to enrollment is not allowed. Treatment with flutamide within 4 weeks prior to enrollment is not allowed. Treatment with all other gonadotropin-releasing hormone (GnRH) analogues or antagonists is allowed.
  • Chemotherapy
  • Biologic therapy
  • Investigational therapy
  • Immunotherapy

4. No use of herbal products that may decrease PSA levels within 4 weeks prior to enrollment

5. No use of systemic steroids greater than the equivalent of 10 mg of prednisone/prednisolone per day within 4 weeks prior to enrollment

6. No prior use of ketoconazole for greater than 7 days

7. No prior radiation therapy or radionuclide therapy for the treatment of metastasis within four weeks prior to enrollment

8. Patients receiving bisphosphonate therapy or denosumab must have been on a stable dose for at least 4 weeks prior to enrollment

9. Patients must maintain ongoing androgen deprivation therapy with a GnRH analogue, antagonist, or bilateral orchiectomy (i.e., surgical or medical castration)

5. Patient History

1. No known or suspected brain metastases (NOTE: patients with treated epidural disease are allowed)

2. No planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery

3. No structurally unstable bone lesions suggesting impending fracture

4. No history of seizure or any condition that may increase the patient's seizure risk (e.g., prior cortical stroke, significant brain trauma). No history of transient ischemic attack (TIA) within 12 months of enrollment

5. No clinically significant cardiovascular disease including:

  • Myocardial infarction (MI) within 6 months
  • Uncontrolled angina within 3 months
  • Congestive heart failure (CHF) with New York Heart Association (NYHA) class 3 or 4, or patients with NYHA class 3 or 4 in the past, unless a screening echocardiogram (echo) or multigated acquisition scan (MUGA) performed within three months demonstrates an ejection fraction (EF) > 45%
  • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes)
  • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
  • Hypotension (systolic blood pressure [BP] < 86 mmHg) or bradycardia (< 50 bpm) at screening
  • Uncontrolled hypertension (systolic BP > 170 mmHg or diastolic BP > 105 mmHg at screening)

6. No gastrointestinal (GI) disorder that negatively affects absorption

7. No major surgery within 4 weeks prior to enrollment

6. Age and performance status

1. Age ≥ 18 years of age

2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

3. Asymptomatic or mildly symptomatic from prostate cancer

7. Required Initial Laboratory Values

1. Granulocytes ≥ 1,500/µL

2. Platelet count ≥ 100,000/µL

3. Hemoglobin ≥ 9 g/dL

4. Creatinine ≤ 2 x upper limits of normal (ULN)

5. Bilirubin ≥ 1.5 x ULN

6. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2 x ULN

7. Albumin ≥ 3 g/dl

8. Serum testosterone ≤ 50 ng/dL (1.7 nmol/L)

Trial Contact Information

Trial Lead Organizations/Sponsors

Alliance for Clinical Trials in Oncology

National Cancer Institute

Astellas Pharma US, Incorporated

Medivation, Incorporated

Biologics, Inc.

Michael MorrisStudy Chair

Trial Sites

U.S.A.
Arizona
  Tucson
 Arizona Cancer Center at UMC Orange Grove
 Parminder Singh Ph: 520-626-9008
 Arizona Cancer Center at University Medical Center North
 Parminder Singh Ph: 520-626-9008
 Arizona Cancer Center at University of Arizona Health Sciences Center
 Parminder Singh Ph: 520-626-9008
Arkansas
  Jonesboro
 NEA Medical Clinic - East Matthews
 Carroll Dean Scroggin Ph: 888-823-5923
  Email: ctsucontact@westat.com
California
  San Francisco
 UCSF Helen Diller Family Comprehensive Cancer Center
 Terence W Friedlander Ph: 877-827-3222
Connecticut
  Hartford
 Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
 Philip J. Stella Ph: 734-712-4673
  Norwich
 Eastern Connecticut Hematology and Oncology Associates
 Dennis E. Slater Ph: 860-886-8362
Florida
  Miami Beach
 CCOP - Mount Sinai Medical Center
 Michael Schwartz Ph: 305-674-2625
  Email: info@msccop.com
  Pensacola
 Sacred Heart Cancer Center at Sacred Heart Hospital
 James F Watkins Ph: 850-416-4611
 Sacred Heart Medical Oncology Group
 James F Watkins Ph: 850-416-4611
Georgia
  Atlanta
 Northside Hospital Cancer Center
 Mansoor N Saleh Ph: 404-303-3355
  Savannah
 Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler
 Mark A. Taylor Ph: 912-350-8568
Idaho
  Boise
 Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
 Philip J. Stella Ph: 734-712-4673
  Post Falls
 Kootenai Cancer Center - Post Falls
 Benjamin Thomas Marchello Ph: 800-648-6274
Illinois
  Chicago
 Cancer and Leukemia Group B
 Michael Morris Ph: 646-422-4469
  Email: morrism@mskcc.org
 Creticos Cancer Center at Advocate Illinois Masonic Medical Center
 Mebea Aklilu Ph: 773-296-5360
  Harvey
 Ingalls Cancer Care Center at Ingalls Memorial Hospital
 Mark F. Kozloff Ph: 708-915-4673
  Email: clinicaltrials@ingalls.org
  Maywood
 Cardinal Bernardin Cancer Center at Loyola University Medical Center
 Elizabeth Henry Ph: 708-226-4357
  Peoria
 Illinois CancerCare - Peoria
 Nguyet A Le-Lindqwister Ph: 800-793-2262
  Quincy
 Quincy Medical Group
 Raymond P Smith Ph: 888-823-5923
  Email: ctsucontact@westat.com
  Springfield
 Regional Cancer Center at Memorial Medical Center
 James L. Wade Ph: 217-876-4740
  Email: kcheek@dmhhs.org
  Urbana
 Carle Cancer Center at Carle Foundation Hospital
 Ronnie F Luyun Ph: 800-446-5532
Indiana
  Fort Wayne
 Fort Wayne Medical Oncology and Hematology
 Sreenivasa Rao Nattam Ph: 260-484-8830
  Email: ledgar@fwmoh.com
  Mishawaka
 Michiana Hematology-Oncology, PC - Mishawaka
 Robin Zon Ph: 574-234-5123
  South Bend
 Memorial Hospital of South Bend
 Thomas Joseph Reid Ph: 800-284-7370
  Westville
 Michiana Hematology Oncology-PC Westville
 Robin Zon Ph: 574-234-5123
Iowa
  Ames
 McFarland Clinic, PC
 Joseph James Merchant Ph: 515-239-2621
  Bettendorf
 Hematology Oncology Associates of the Quad Cities
 Shobha R. Chitneni Ph: 563-355-7733
  Email: kedaprile@rccqc.com
  Davenport
 Genesis Regional Cancer Center at Genesis Medical Center
 George Kovach Ph: 800-446-6088
  Email: werners@genesishealth.com
  Iowa City
 Holden Comprehensive Cancer Center at University of Iowa
 Daniel A Vaena Ph: 800-237-1225
 Veterans Affairs Medical Center - Iowa City
 Daniel A Vaena Ph: 800-237-1225
  Mason City
 Mercy Cancer Center at Mercy Medical Center - North Iowa
 Arvind Y Vemula Ph: 800-433-3883
Maine
  Augusta
 Harold Alfond Center for Cancer Care
 Thomas Henry Openshaw Ph: 207-973-4274
  Bangor
 CancerCare of Maine at Eastern Maine Medical Center
 Thomas Henry Openshaw Ph: 207-973-4274
Maryland
  Frederick
 Frederick Memorial Hospital Regional Cancer Therapy Center
 Elhamy Eskander Ph: 240-566-3584
  Email: clinicaltrials@fmh.org
  Westminster
 Carroll County Cancer Center
 Flavio W Kruter Ph: 877-441-7957
Massachusetts
  Newton
 Newton-Wellesley Hospital
 Caroline C Block Ph: 888-823-5923
  Email: ctsucontact@westat.com
Michigan
  Ann Arbor
 Saint Joseph Mercy Cancer Center
 Philip J. Stella Ph: 734-712-4673
  Detroit
 Josephine Ford Cancer Center at Henry Ford Hospital
 Robert Anthony Chapman Ph: 313-916-1784
  Escanaba
 Green Bay Oncology, Limited - Escanaba
 Anthony J. Jaslowski Ph: 800-432-6049
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Gilbert D Padula Ph: 616-685-5225
 Lacks Cancer Center at Saint Mary's Health Care
 Gilbert D Padula Ph: 616-685-5225
  Iron Mountain
 Green Bay Oncology - Iron Mountain
 Anthony J. Jaslowski Ph: 800-432-6049
  Livonia
 St. Mary Mercy Hospital
 Philip J. Stella Ph: 734-712-4673
  Saginaw
 Seton Cancer Institute at Saint Mary's - Saginaw
 Philip J. Stella Ph: 734-712-4673
Minnesota
  Coon Rapids
 Mercy and Unity Cancer Center at Mercy Hospital
 Daniel M Anderson Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Duluth
 CCOP - Duluth
 Bret E Friday Ph: 888-203-7267
  Maplewood
 HealthEast Cancer Care at St. John's Hospital
 Daniel M Anderson Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Minneapolis
 Veterans Affairs Medical Center - Minneapolis
 Sharon D Luikart Ph: 612-467-2800
  Saint Louis Park
 Park Nicollet Cancer Center
 Daniel M Anderson Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Saint Paul
 Regions Hospital Cancer Care Center
 Daniel M Anderson Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Shakopee
 St. Francis Cancer Center at St. Francis Medical Center
 Daniel M Anderson Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Stillwater
 Lakeview Hospital
 Daniel M Anderson Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Woodbury
 Minnesota Oncology - Woodbury
 Daniel M Anderson Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
Missouri
  Cape Girardeau
 Saint Francis Medical Center
 James L. Wade Ph: 217-876-4740
  Email: kcheek@dmhhs.org
  Chesterfield
 Saint Luke's Hospital
 Donald F. Busiek Ph: 314-205-6936
  Columbia
 Ellis Fischel Cancer Center at University of Missouri - Columbia
 Donald C Doll Ph: 573-882-7440
  Saint Louis
 Missouri Baptist Cancer Center
 Alan Philip Lyss Ph: 800-392-0936
 Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
 Joel Picus Ph: 800-600-3606
  Email: info@siteman.wustl.edu
  Springfield
 St. John's Regional Health Center
 Jay W Carlson Ph: 800-821-7532
  Email: sherrijr@iora.org
Montana
  Billings
 St. Vincent Healthcare Cancer Care Services
 Benjamin Thomas Marchello Ph: 800-648-6274
  Bozeman
 Bozeman Deaconess Cancer Center
 Benjamin Thomas Marchello Ph: 800-648-6274
  Butte
 St. James Healthcare Cancer Care
 Benjamin Thomas Marchello Ph: 800-648-6274
Nebraska
  Omaha
 Methodist Estabrook Cancer Center
 Ralph Hauke Ph: 402-354-5144
Nevada
  Las Vegas
 HealthCare Partners Medical Group Oncology/Hematology-San Martin
 John Allan Ellerton Ph: 702-384-0013
 HealthCare Partners Medical Group Oncology/Hematology-Tenaya
 John Allan Ellerton Ph: 702-384-0013
New Hampshire
  Concord
 New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
 Frederick M. Briccetti Ph: 800-339-6484
  Dover
 Seacoast Cancer Center at Wentworth - Douglass Hospital
 Taylor M Ortiz Ph: 603-740-2150
  Hooksett
 New Hampshire Oncology - Hematology, PA - Hooksett
 Frederick M. Briccetti Ph: 800-339-6484
  Laconia
 Lakes Region General Hospital
 Frederick M. Briccetti Ph: 800-339-6484
New Mexico
  Albuquerque
 University of New Mexico Cancer Center
 Richard C Lauer Ph: 505-272-6972
  Las Cruces
 Memorial Medical Center
 Richard C Lauer Ph: 505-272-6972
  Santa Fe
 New Mexico Cancer Care Associates
 Richard C Lauer Ph: 505-272-6972
New York
  Brooklyn
 Maimonides Cancer Center at Maimonides Medical Center
 Kevin Becker Ph: 203-785-5702
  New Hyde Park
 Monter Cancer Center of the North Shore-LIJ Health System
 Xinhua Zhu Ph: 516-562-3467
  New York
 Memorial Sloan-Kettering Cancer Center
 Michael Morris Ph: 212-639-7202
  Syracuse
 SUNY Upstate Medical University Hospital
 Sam Benjamin Ph: 315-464-5476
North Carolina
  Asheboro
 Randolph Hospital
 James M Granfortuna Ph: 336-832-0821
  Chapel Hill
 Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
 Young Whang Ph: 877-668-0683
  Email: cancerclinicaltrials@med.unc.edu
  Greensboro
 Moses Cone Regional Cancer Center at Wesley Long Community Hospital
 James M Granfortuna Ph: 336-832-0821
  Kinston
 Kinston Medical Specialists
 Peter R. Watson Ph: 252-559-2200
  Reidsville
 Annie Penn Cancer Center
 James M Granfortuna Ph: 336-832-0821
  Washington
 Marion L. Shepard Cancer Center at Beaufort County Hospital
 John J Inzerillo Ph: 252-975-4308ext104
  Email: sbell@brhealthsystem.org
  Winston-Salem
 Wake Forest University Comprehensive Cancer Center
 Christopher Y. Thomas Ph: 434-243-6143
North Dakota
  Bismarck
 Medcenter One Hospital Cancer Care Center
 Preston D. Steen Ph: 701-234-6161
  Fargo
 Roger Maris Cancer Center at MeritCare Hospital
 Preston D. Steen Ph: 701-234-6161
 Sanford Clinic North-Fargo
 Preston D. Steen Ph: 701-234-6161
  Grand Forks
 Altru Cancer Center at Altru Hospital
 Grant R Seeger Ph: 701-780-6520
Ohio
  Akron
 Summa Center for Cancer Care at Akron City Hospital
 Jennifer E Payne Ph: 330-375-6101
  Barberton
 Barberton Citizens Hospital
 Jennifer E Payne Ph: 330-375-6101
  Cleveland
 Case Comprehensive Cancer Center
 Matthew M. Cooney Ph: 800-641-2422
 Cleveland Clinic Cancer Center at Fairview Hospital
 Anjali S Advani Ph: 866-223-8100
 Cleveland Clinic Taussig Cancer Center
 Anjali S Advani Ph: 866-223-8100
  Columbus
 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
 Amir Mortazavi Ph: 866-627-7616
  Email: osu@emergingmed.com
  Independence
 Cleveland Clinic Taussig Cancer Center
 Anjali S Advani Ph: 866-223-8100
  Mayfield Heights
 Hillcrest Cancer Center at Hillcrest Hospital
 Anjali S Advani Ph: 866-223-8100
  Medina
 Summa Health Center at Lake Medina
 Jennifer E Payne Ph: 330-375-6101
  Orange Village
 UHHS Chagrin Highlands Medical Center
 Matthew M. Cooney Ph: 800-641-2422
  Sandusky
 North Coast Cancer Care, Incorporated
 Anjali S Advani Ph: 866-223-8100
  Strongsville
 Cleveland Clinic Foundation - Strongsville
 Anjali S Advani Ph: 866-223-8100
  Westlake
 UHHS Westlake Medical Center
 Matthew M. Cooney Ph: 800-641-2422
  Wooster
 Cleveland Clinic - Wooster
 Anjali S Advani Ph: 866-223-8100
Oklahoma
  Lawton
 Cancer Centers of Southwest Oklahoma, LLC - Lawton
 Nadim F. Nimeh Ph: 877-231-4440
  Oklahoma City
 Oklahoma University Cancer Institute
 Sindhu Singh Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
Oregon
  Corvallis
 Good Samaritan Hospital
 Kimberly A McGregor Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
  Newberg
 Providence Newberg Medical Center
 Alison K Conlin Ph: 503-215-6412
  Oregon City
 Willamette Falls Hospital
 Alison K Conlin Ph: 503-215-6412
  Portland
 Providence Cancer Center at Providence Portland Medical Center
 Alison K Conlin Ph: 503-215-6412
Pennsylvania
  Gettysburg
 Adams Cancer Center
 Amir Tabatabai Ph: 877-441-7957
  Langhorne
 St. Mary Regional Cancer Center
 Robert C. Reilly Ph: 215-710-4585
  Pittsburgh
 Allegheny Cancer Center at Allegheny General Hospital
 Shifeng S Mao Ph: 877-284-2000
  York
 WellSpan Health
 Amir Tabatabai Ph: 877-441-7957
South Carolina
  Charleston
 Charleston Hematology Oncology Associates PA-St. Francis
 James Michael Orcutt Ph: 843-720-8386
  Email: elizabeth.strojny@roperstfrancis.com
  Greenville
 Bon Secours St. Francis Health System
 James Dewitt Bearden Ph: 800-486-5941
South Dakota
  Sioux Falls
 Avera Cancer Institute
 Addison R Tolentino Ph: 800-657-4377
  Email: Jan.Healy@avera.org
 Sanford Cancer Center at Sanford USD Medical Center
 Miroslaw A Mazurczak Ph: 605-328-1367
Virginia
  Hampton
 Virginia Oncology Associates - Hampton
 Paul R. Conkling Ph: 757-873-9400
  Lynchburg
 Lynchburg Hematology-Oncology Clinic
 Craig Swainey Ph: 804-628-1939
  Richmond
 Virginia Cancer Institute - West End
 Craig Swainey Ph: 804-628-1939
 Virginia Commonwealth University Massey Cancer Center
 Craig Swainey Ph: 804-628-1939
  Winchester
 Shenandoah Oncology Associates, PC
 Craig Swainey Ph: 804-628-1939
Washington
  Bellingham
 St. Joseph Cancer Center
 Gary E Goodman Ph: 206-386-2323
  Email: patra.grevstad@swedish.org
  Poulsbo
 Harrison Poulsbo Hematology and Onocology
 Gary E Goodman Ph: 206-386-2323
  Email: patra.grevstad@swedish.org
  Seattle
 Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
 Gary E Goodman Ph: 206-386-2323
  Email: patra.grevstad@swedish.org
West Virginia
  Huntington
 St. Mary's Regional Cancer Center at St. Mary's Medical Center
 Arvinder S Bir Ph: 888-823-5923
  Email: ctsucontact@westat.com
Wisconsin
  Eau Claire
 Center for Cancer Treatment & Prevention at Sacred Heart Hospital
 Seth Olusegun Fagbemi Ph: 715-389-4457
 Marshfield Clinic Cancer Care at Regional Cancer Center
 Seth Olusegun Fagbemi Ph: 715-389-4457
  Fond Du Lac
 Central Wisconsin Cancer Program at Agnesian HealthCare
 Michael W Jones Ph: 800-494-2927
  Green Bay
 Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
 Anthony J. Jaslowski Ph: 800-432-6049
 St. Mary's Hospital Medical Center - Green Bay
 Anthony J. Jaslowski Ph: 800-432-6049
 St. Vincent Hospital Regional Cancer Center
 Anthony J. Jaslowski Ph: 800-432-6049
 Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
 Dhimant R. Patel Ph: 800-252-2990
  La Crosse
 Gundersen Lutheran Center for Cancer and Blood
 Michael O Ojelabi Ph: 608-775-2385
  Email: cancerctr@gundluth.org
  Manitowoc
 Holy Family Memorial Medical Center Cancer Care Center
 Anthony J. Jaslowski Ph: 800-432-6049
  Marshfield
 Marshfield Clinic - Marshfield Center
 Seth Olusegun Fagbemi Ph: 715-389-4457
 Saint Joseph's Hospital
 Seth Olusegun Fagbemi Ph: 715-389-4457
  Milwaukee
 Aurora Sinai Medical Center
 Dhimant R. Patel Ph: 800-252-2990
  Mukwonago
 D.N. Greenwald Center
 Timothy R Wassenaar Ph: 262-928-7878
  Oconomowoc
 Regional Cancer Center at Oconomowoc Memorial Hospital
 Timothy R Wassenaar Ph: 262-928-7878
  Oconto Falls
 Green Bay Oncology, Limited - Oconto Falls
 Anthony J. Jaslowski Ph: 800-432-6049
  Rice Lake
 Marshfield Clinic - Indianhead Center
 Seth Olusegun Fagbemi Ph: 715-389-4457
  Sheboygan
 Saint Nicholas Hospital
 Anthony J. Jaslowski Ph: 800-432-6049
  Stevens Point
 Marshfield Clinic at Saint Michael's Hospital
 Seth Olusegun Fagbemi Ph: 715-389-4457
 Saint Michael's Hospital Cancer Center
 Seth Olusegun Fagbemi Ph: 715-389-4457
  Sturgeon Bay
 Green Bay Oncology, Limited - Sturgeon Bay
 Anthony J. Jaslowski Ph: 800-432-6049
  Waukesha
 Waukesha Memorial Hospital Regional Cancer Center
 Timothy R Wassenaar Ph: 262-928-7878
  West Allis
 Aurora Women's Pavilion of West Allis Memorial Hospital
 Dhimant R. Patel Ph: 800-252-2990
  Weston
 Diagnostic and Treatment Center
 Seth Olusegun Fagbemi Ph: 715-389-4457
 Marshfield Clinic - Weston Center
 Seth Olusegun Fagbemi Ph: 715-389-4457

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01949337
ClinicalTrials.gov processed this data on May 14, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top